Plain-English translation of NCT06611020 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This trial is testing whether HPV vaccination given after cervical treatment can help prevent the disease from returning. Researchers will follow two groups of patients — those who choose to receive the vaccine after their cervical procedure and those who do not — to compare how many experience HPV recurrence over time. The goal is to understand whether this vaccination approach offers extra protection.
Even after successful cervical treatment, some patients experience HPV recurrence. Doctors want to know whether giving the vaccine after treatment — rather than before disease develops — can reduce the risk of the disease coming back and improve long-term outcomes.
You likely qualify if…
You likely don't qualify if…
After your cervical treatment, you will be asked whether you want to receive HPV vaccination. Researchers will then monitor both groups — vaccinated and unvaccinated — over time to track whether HPV returns. This involves periodic follow-up visits and testing to measure the rate of recurrence in each group.
AI-generated summary from trial data · Jun 30, 2026 · Not medical advice
Italy
Enrollment target
~600 participants
Started
January 2020
Primary completion
January 2025
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years and older
Sex
Female only
Last updated on clinicaltrials.gov in September 2024.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Giorgio Bogani, ph.d.
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.